Pharmaceuticals

The “Stop Sneeze to Wheeze” Initiative: Alkem Laboratories Takes Lead in Combating Respiratory Diseases

Person sneezing illustrating the importance of the “Stop Sneeze to Wheeze” initiative in combating Allergic Rhinitis and Asthma

In a bid to tackle the global issue of respiratory diseases, Alkem Laboratories Ltd has launched the “Stop Sneeze to Wheeze” initiative during World Allergy Week. The campaign highlights the importance of understanding and addressing the coexistence of Allergic Rhinitis and Asthma – a phenomenon often referred to as “One Airway, One Disease”.

Allergic Rhinitis is an inflammation of the nasal passages, usually triggered by allergens such as pollen and dust. Notably, if left unattended, this can evolve into asthma, which is characterized by airway inflammation and sensitivity. With millions affected by these co-existing conditions, Alkem’s initiative aims at early diagnosis and effective management to enhance patients’ quality of life.

The initiative comprises awareness drives, camps, and clinics designed to educate the public. “The incidence of asthma and Allergic Rhinitis is on the rise. It’s imperative to educate the public on early warning signs and adherence to treatment plans,” said Mr. Sudipta Roy, President, Head – Acute business at Alkem Laboratories Ltd.

Furthermore, Alkem points patients and the general public to the Healthy Lungs portal for credible information on lung diseases.

Author

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *